OPKO Health, Inc. (NASDAQ:OPK) Stock Now Rated "Hold" by Sell-Side Analysts

Key Points

• Analysts have a consensus “Hold” rating on OPKO Health, with one sell, three hold, one buy and one strong-buy rating. The average 12-month price target is $1.55.
• Institutional investors and hedge funds own 64.63% of OPKO’s shares, while several firms recently initiated positions in the company.
• OPKO’s latest quarterly results exceeded expectations, reporting an adjusted loss of $0.01 per share versus estimates of $0.08 and revenue of $163.58 million, up 4.3% year over year.

Shares of OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) have received a consensus recommendation of "Hold" from the six brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $1.55.

OPK has been the topic of a number of research analyst reports. HC Wainwright reissued a "buy" rating on shares of OPKO Health in a research note on Wednesday, July 29th. Wall Street Zen upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a research report on Saturday, June 6th. Zacks Research raised shares of OPKO Health from a "hold" rating to a "strong-buy" rating in a report on Monday, September 28th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of OPKO Health in a research report on Thursday, August 13th.

Institutional Investors Weigh In On OPKO Health

Several institutional investors have recently bought and sold shares of the company. Two Sigma Securities LLC acquired a new position in shares of OPKO Health during the second quarter valued at approximately $27,000. Apella Capital LLC purchased a new stake in shares of OPKO Health during the first quarter worth approximately $34,000. EP Wealth Advisors LLC purchased a new stake in shares of OPKO Health during the second quarter worth approximately $45,000. Diversify Advisory Services LLC acquired a new position in OPKO Health in the 2nd quarter valued at $37,000. Finally, Abel Hall LLC acquired a new position in OPKO Health in the 1st quarter valued at $38,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.56 on Friday. The company has a market capitalization of $1.16 billion, a P/E ratio of -17.33 and a beta of 1.51. The business's 50 day moving average is $1.51 and its two-hundred day moving average is $1.35. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28. OPKO Health has a 12-month low of $0.98 and a 12-month high of $1.75.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Monday, July 27th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.07. The business had revenue of $163.58 million during the quarter, compared to analysts' expectations of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The business's revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.19) earnings per share. Analysts expect that OPKO Health will post -0.23 EPS for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.

OPKO's pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.